Notice of Annual General Meeting - Clarification

About this update from Probiotix Health Plc

5 June 2025                                                                                                                                   ProBiotix Health plc ("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")   Notice of Annual General Meeting - Clarification   ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces, for the avoidance of doubt, that Resolution 3 in the Company's Notice of Annual General Meeting is for the re-election of Steen Andersen, the Company's Chief Executive Officer, as a Director of the Company. The reference to Steen "Anderson" is a typographical error. Existing Forms of proxy for use at the Annual General Meeting remain valid.   For further information, please contact:   ProBiotix Health plc https://probiotixhealth-ir.com/   [email protected] Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations   Peterhouse Capital Limited Aquis Corporate Adviser and Broker       Mark Anwyl Duncan Vasey   Tel: 020 7469 0930   Notes to Editors:   ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.   The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.    

View stock analysis, news, and events for Probiotix Health Plc